Halo Pharmaceutical, Inc.’s Post

Join me for an insightful panel discussion at the BIO International Convention in San Diego on June 5. Our session, "Evolution of the IRA: A New-Year, a Potential New Administration, Yet Tackling the Same Access and Affordability Challenges," will feature expert panelists like William Roth, Gerry Gleeson, Albert Thigpen, and William Sarraille. They will demystify how IRA will change the landscape for emerging pharmaceutical companies and put recent developments in plain language. Don't miss out on this opportunity to stay ahead of the curve in the ever-changing world of drug pricing and Medicare negotiation. #BIO2024 #IRA #drugpricing #medicarenegotiation

Eli Lilly’s leap to #biopharma leadership: What can we learn from their journey? This recent Fortune article describes how Eli Lilly and Company has undergone a remarkable transformation, evolving from a slower-paced pharmaceutical company to a top 10 spot as one of the world’s most valuable companies. Key to this success has been groundbreaking treatments like Mounjaro for diabetes and the obesity drug Zepbound, which have significantly boosted their revenues and market value. Visionary #leadership and strategic focus of CEO David Ricks and CSO Dan Skovronsky on cutting-edge treatments and relentless pursuit of medical advancements, such as Alzheimer’s Disease and curative gene therapies, continue to set new standards in healthcare. “Now [Lilly is] thinking about playing the game differently, as well as just playing the same game better than other people.” - Mike Rea #pharmaceuticalinnovation #asymmetriclearning https://lnkd.in/ekGAD96N

Still unsure where to start with #DSCSA or what to do next? The two dispensers Kevin Capatch and Max Peoples assure you that you’re not alone on this journey. Enough people have gone before you to provide guidance. Kevin Capatch warns, “I don't think delaying at this moment in time any longer has any advantage to anybody.” Max Peoples echoes, “It's hard to come down too hard on you if you're doing something. If you're leaving your head in the sand, you're showing no effort, no progress, you're making it very easy for them to make an example out of you!” Shared advice: If you don’t have a solution provider, find one. https://lnkd.in/euGEJVyr #OCI recommends to check that your provider is truly interoperable in the current system. Find a number of compatible providers at https://lnkd.in/eFfRbZrD. These companies have proven that their systems communicate seamlessly with each other. #OCI #Dispensers #Pharmaceuticals #DSCSA #RegulatoryCompliance

Continuing with the theme that detailed estimates of future market potential have little role in development decisions or success, this article by David Shaywitz, MD, PhD in Timmerman Report titled "What if you can't pick winnders in R&D?" is must reading. In discussing examples of almost-missed opportunities ranging from bortezomib (Velcade) and pembrolizumab (Keytruda) to GLP-1 agnoists (especially for obesity), Shaywitz concludes: “In a futile effort to domesticate uncertainty, many R&D organizations, especially when things seem to be going poorly, decide they will improve decision making by imposing stricter discipline, and start affixing all sorts of quantification (e.g. probability of technical success, estimated net present value [NPV]) across R&D. These tend to be falsely precise numbers that typically provide far more illusory comfort than true insight.” Center for Integration of Science and Industry at Bentley University @pharmaceutical, #innovation

A few months back, the team at Health Connect Solutions reached out looking to develop a web-based application in partnership with pharmaceutical companies that would give nurses and frontline healthcare staff instant access to critical drug information. Teaming up with Jan Mertlik, we were able to bring this product to life in under a month with the launch of the first two DrugApp applications - an Anti-Cancer Oral Medication Database, and a Prostate Cancer Drug Interaction tool. With positive feedback from frontline staff, there are now two additional applications currently in development getting set to launch late summer/early fall. It's an exciting project here at Launch as - while it may be only one small piece in the big picture, these tools will have a positive impact on the quality and speed of care within our healthcare system. https://www.drugapp.ca/

UP AFTER EARNINGS -  Eli Lilly (LLY) up 12% Under Armour (UAA) up 11% Yeti (YETI) up 8% US Foods (USFD) up 7%  Datadog (DDOG) up 6% CyberArk (CYBR) up 6% Shift4 Payments (FOUR) up 4%  Penn Entertainment (PENN) up 2% Six Flags Entertainment (FUN) up 1% DOWN AFTER EARNINGS -  Plug Power (PLUG) down 6%  Elanco (ELAN) down 3% Bumble (BMBL) down 40%  JFrog (FROG) down 25%  Sonos (SONO) down 16% SolarEdge (SEDG) down 16% Fastly (FSLY) down 15%  Warner Bros. Discovery (WBD) down 10% #buckleup Bumble pulling back, people cant even afford to go on dates

🚀 Exciting News! We’re Thrilled to Announce Our New Partnership with Aurobindo Pharma USA, Inc.! 🚀 We’re proud to partner with Aurobindo to bring their employees exclusive savings through Previ! 🎉 Here’s the deal: Previ empowers employees to save $1,200+ per year on essential services like T-Mobile and AT&T cell phone service— while providing them premium and unlimited plans. Better plans and less 💸. 👉 What’s in it for Aurobindo USA? ✔️ $0 cost to the company ✔️ No hidden fees, no complicated terms—just straightforward savings ✔️ Easy implementation with full support from the Previ team Through this partnership, Aurobindo USA is taking a proactive step in enhancing their employees’ financial wellness without any extra cost. 💼🙌 We can’t wait to see the impact of these savings for their teams! 💪 Stay tuned for more updates as we continue to help companies bring financial benefits that really make a difference.

Loved the Lilly Oscar Night Ad: On Three Levels The Lilly ad on Oscar night taking aim at the “vanity” uses of #glp1 drugs was powerfully effective on three fronts: two you probably readily saw, but another you may not have. The ad offered three messages: (1) health equity, (2) combatting drug shortages, and (3) the company is compliant and isn’t going to be an easy mark for an off-label FCA or other enforcement action. Health Equity and Shortages: At one level, the ad was a strong statement about both health equity and the shortage implications of the “vanity” uses of a drug. Kudos to Lilly for speaking against self-interest in a strong patient-centered voice that championed an important public health issue—preserving access for needy patients in a supply-constrained market. It’s a use of much maligned DTC advertising in a manner that is commendable and thought-provoking. Compliance: But, in addition to that altruism, there lurked a very smart compliance effort. With off-label use rampant in the GLP-1 space, it’s inevitable that an off-label promotion investigation is looming out there. In that context, the ad is a tangible and very public statement that, as a corporate entity, Lilly is committed to on label use. “Positive” Compliance Efforts: I call these kinds of compliance influenced strategies “positive” compliance. From years of defending off label promotion allegations, I can tell you that what is difficult about them is that a company often lacks a “positive” story to tell from a compliance perspective, leaving it vulnerable to its compliance identity being fashioned by the bad actors at the company who engage in non-compliant conduct. “Positive” compliance aims not just to prevent bad things from happening but to take “positive” steps to attack root causes—in this case—of off label use. For example, imagine you have a drug that is used significantly off label. You have done all the traditional things to address the issue—training sales reps, policies and procedures, monitoring, etc.— but the off label use is really high—notwithstanding all that. What would a “positive” compliance strategy look like? Well, what if medical affairs looked at where the off label prescriptions were coming from and actually sent medical liaisons to “counter detail” the off label use driven by those prescribers? I’ve helped employ exactly that “positive” compliance strategy, and I have seen it shut down a US Attorney’s Office False Claims Act investigation. Compliance can be more than engaging in well-worn “blocking and tackling” exercises like that annual off-label promotion training session—when done right, it’s a reflection of an innovative company’s identity as an innovator. #offlabel #healthcareinnovation #healthcarecompliance #fda #healthcarefraud #obesity #healthequity #fca #whistleblowers #drugshortages #dtc

At 21 years old I was hired by Pfizer to be a pharmaceutical rep. What I loved about the job was 1) it taught me about people 2) it showed me not to adopt other people’s assumptions or self-imposed limitations 3) I got to spend the entire day learning from Doctors that gladly mentored me 4) while I wasn’t treating patients directly, I was giving their doctor guidance on how to help people with serious infections and devastating diseases. By showing them how NOT to use these products I represented, I also helped to keep people safe. What I didn’t like was the “competition” going on all around me. The reports comparing my sales to people all over the US. This made me feel worse. It wasn’t why I was there. Much to the chagrin of a few managers I wasn’t competing with my colleagues. I was showing up as the best version of myself trying to educate and counsel, not sell. Their reports sat in a binder and collected dust. My books of business always grew, but not because I was hunting down my colleagues on some list. Today I operate the same way. I’m not competing with other research teams. Sure, I get that this lights some people’s fires and I’m not judging them. My view doesn’t have to be yours. But here’s my take: There’s more than enough important work for all of us. Ample grant opportunities, spots on stage to talk about data. Bottom line: There are too many patients that need our help. They need us to compete to be the best version of ourselves. By doing the very best work we can, focusing on innovation and being open to being wrong, we can advance faster. They need us to show up, and they need us to start collaborating in areas lacking meaningful progress. That’s what we do at The Alzheimer's Pathobiome Initiative (AlzPI) and I’m in love with the model. Everyone is parking their egos and leveraging their expertise while learning from experts in other disciplines. Happy Monday Everyone. Whatever you’re working on, I’m rooting for you. 🙌🏽

This Thanksgiving, we’re grateful for you! As we celebrate Thanksgiving, we at Novozen Healthcare want to take a moment to reflect on the incredible journey we’ve had this year—made possible by YOU. To our clients, partners, and candidates: Thank you for your trust, collaboration, and support. You are at the heart of everything we do, and your success is our biggest motivator. This season is a perfect reminder of the power of gratitude and partnership. Together, we’ve tackled challenges, celebrated wins, and built something truly meaningful. From all of us at Novozen Healthcare, we wish you and your loved ones a joyful Thanksgiving filled with warmth, laughter, and gratitude. Let’s continue to grow and succeed together! What are you thankful for this year? Share your thoughts in the comments—we’d love to hear from you! Happy Thanksgiving! TARUN KUMAR Ramya Sri Ram Kiran Janaki Gandhavarapu Ganesh Venkat Naveen Kumar Gadde Mareedu Lokesh Siva Sai Ram Nikhita Yaram #Thanksgiving2024 #Gratitude #Collaboration #Success #HealthcareInnovation #MedicalDevices #Pharmaceuticals #Biotechnology #QualityAssurance #RegulatoryAffairs #ManufacturingExcellence #ClinicalResearch #ValidationSpecialists #ISO13485 #FDACompliance #GMP #GLP #R&D #ProcessImprovement #Automation #CleanroomTechnology #SOPDevelopment #HealthcareRecruitment #PharmaCareers #MedicalDeviceCareers #PharmaInnovation #DeviceManufacturing #LabEquipmentValidation #Therapeutics #DrugDevelopment #QualityControl #HealthcareStaffing #BiotechCareers #MedicalDeviceManufacturing #RegulatoryCompliance #PharmaManufacturing #HealthcareConsulting #ValidationEngineering #ClinicalTrials #MedicalDeviceRegulation #PatientSafety #PharmaTech #DataIntegrity #HealthcareSolutions #LaboratoryValidation #LifeSciencesRecruitment #PharmaTalent #DeviceDesign #PharmaQuality #HealthTech #PharmaExcellence #BiotechInnovation #RegulatorySupport #HealthcareCompliance #PrecisionMedicine #PharmaSuccess